Anacor Pharmaceuticals Receives Significant Investment to Support Neglected Disease Research

  Anacor Pharmaceuticals Receives Significant Investment to Support Neglected
  Disease Research

Business Wire

PALO ALTO, Calif. -- April 08, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has signed a
research agreement with the Bill & Melinda Gates Foundation (the Gates
Foundation) to discover drug candidates intended to treat two filarial worm
diseases (onchocerciasis, or river blindness, and lymphatic filariasis,
commonly known as elephantiasis) and tuberculosis (TB). Additionally, Anacor
will create an expanded library of boron compounds to screen for additional
potential drug candidates to treat neglected diseases and will provide access
to the expanded library compounds for neglected disease research to the Gates
Foundation, and others, including academic, governmental and other non-profit
institutions or equivalent entities. Under the agreement, Gates Foundation
will pay Anacor $17.7 million as well as invest $5 million in Anacor common
stock.

“We are excited to continue our research in neglected diseases through this
landmark research agreement with the Gates Foundation, which is known for its
dedication to solving global health issues,” said David Perry, Anacor’s Chief
Executive Officer. “Anacor is committed to applying our chemistry to find new
treatments for neglected diseases, and it is with the support of partners like
the Gates Foundation that we can fulfill that commitment.”

“Anacor’s boron chemistry platform can help to discover and develop drug
candidates that address significant unmet needs for patients suffering from
neglected diseases,” said Trevor Mundel, President of Global Health, Bill &
Melinda Gates Foundation. “We are pleased to fund this research collaboration
as well as invest in Anacor to help improve the lives of the millions of
people in developing countries who are impacted by these diseases.”

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK‘052),
a systemic antibiotic for the treatment of infections caused by Gram-negative
bacteria, which previously was licensed to GlaxoSmithKlineLLC, or GSK. GSK
will be returning all rights to the compound to us and we are considering our
options for further development, if any, of this compound. We have discovered
three other compounds that we have out-licensed for further development — two
compounds for the treatment of animal health indications that are licensed to
Eli Lilly and Company, or Lilly, and AN5568, also referred to as SCYX-7158,
for human African trypanosomiasis (HAT, or sleeping sickness), which is
licensed to Drugs for Neglected Diseases initiative, or DNDi. We also have a
pipeline of other internally discovered topical and systemic boron-based
compounds in development. For more information, visit http://www.anacor.com.

Forward-Looking Statements

This press release may contain forward-looking statements that relate to
future events including the development of drug candidates to treat
onchocerciasis, lymphatic filariasis and tuberculosis and the creation of a
library of boron-based compounds to screen for potential drug candidates for
other neglected diseases. These forward looking statements involve known and
unknown risks, uncertainties and other factors that could cause actual levels
of activity, performance or achievement to differ materially from those
expressed or implied by these forward-looking statements, including risks
related to the ability of the parties to collaborate successfully to develop
drug candidates, the results of future drug discovery, development and
commercialization efforts, including proof of safety and efficacy in clinical
trials, the ability to obtain regulatory approvals for drug candidates
identified through the collaboration, and the introduction of competing
therapies by other companies. These statements reflect the views of Anacor as
of the date of this press release with respect to future events and, except as
required by law, it undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise after the date of this press release.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
 
Press spacebar to pause and continue. Press esc to stop.